Management of residual shunts after initial percutaneous patent foramen ovale closure: A single center experience with immediate and long-term follow-up
Background: Moderate‐to‐large residual shunts following percutaneous patent foramen ovale (PFO) closure are clinically important and associated with recurrent neuroembolic events. However, their management has not been clearly established in clinical practice. We report our experience in patients of...
Gespeichert in:
Veröffentlicht in: | Catheterization and cardiovascular interventions 2010-07, Vol.76 (1), p.145-150 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 150 |
---|---|
container_issue | 1 |
container_start_page | 145 |
container_title | Catheterization and cardiovascular interventions |
container_volume | 76 |
creator | Diaz, Tulio Cubeddu, Roberto J. Rengifo-Moreno, Pablo A. Cruz-Gonzalez, Ignacio Solis-Martin, Jorge Buonanno, Ferdinando S. Inglessis, Ignacio Palacios, Igor F. |
description | Background: Moderate‐to‐large residual shunts following percutaneous patent foramen ovale (PFO) closure are clinically important and associated with recurrent neuroembolic events. However, their management has not been clearly established in clinical practice. We report our experience in patients of these patients with a prior history of cryptogenic stroke and/or transient ischemic attack (TIA). Methods: All patients undergoing percutaneous PFO closure were routinely screened at six‐months for residual shunts using transthoracic 2D echocardiography with antecubital administration of agitated saline contrast and color flow Doppler. Patients with evidence of moderate‐to‐large residual shunts were selected to undergo reintervention with shunt closure. Postreintervention follow‐up was performed at 24‐hr, 30 days, and every six months thereafter. Clinical predictors of the moderate‐to‐large residual shunts, and the feasibility, safety and long‐term efficacy of percutaneous residual shunt closure using a second device implant were examined. Results: Between 1995 and 2007, a total of 424 patients underwent PFO closure. Of these, 5% (21/424) had moderate‐to‐large residual shunts. Baseline characteristics among patients with moderate‐to‐large residual shunts and those with only none or small defects (n = 403) were similar. Multivariate analysis identified the 24‐hr postprocedure shunt as the only independent predictor of residual shunting at six months. Of the 21 study patients with moderate‐to‐large residual shunt (mean age, 47 ± 14), one underwent successful elective surgical repair, while the remaining 20 underwent transcatheter closure using a second device. The technique was successful in 95% (19/20), and all but one patient had complete shunt closure at six months of their percutaneous reintervention. We report no deaths, recurrent strokes or TIAs during the long‐term mean follow‐up period of 2.9 years. Conclusions: Our study suggests that in patients with moderate‐to‐large residual PFO shunts, percutaneous reintervention using a second device implant is safe and effective. © 2010 Wiley‐Liss, Inc. |
doi_str_mv | 10.1002/ccd.22475 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733568134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733568134</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3625-4a752a96d46a7b80f6a6de2be74abc91403fe6f6641759874047a34ac66eafb3</originalsourceid><addsrcrecordid>eNp1kctu1DAUhi0EohdY8ALIO8QireM49oRdFWhBGgoSlcrOOnGOpwbnUjth2jfp4-Ih0-5Y2Tr6_k865yfkTc5Ocsb4qTHtCedClc_IYV5ynikufz7f__NKyANyFOMvxlglefWSHHBWqlWKHpKHr9DDBjvsJzpYGjC6dgZP483cT5GCnTBQ17vJpeGIwcwT9DjMkY4w7UJ2CJDSdPgDHqnxQ5wDfqBnNLp-s5skKCnwLoUd9gbp1k031HUdti4pKPQt9UO_yRLWJZ33wzabx1fkhQUf8fX-PSZX55-u6s_Z-tvFl_psnZlC8jIToEoOlWyFBNWsmJUgW-QNKgGNqXLBCovSSilyVVYrJZhQUAgwUiLYpjgm7xbtGIbbGeOkOxcNer9sqVVRlHKVFyKR7xfShCHGgFaPwXUQ7nXO9K4GnWrQ_2pI7Nu9dW7Snk_k490TcLoAW-fx_v8mXdcfH5XZknBxwrunBITfWqoikdeXF_py_f1HzdW1Pi_-Am1wpAU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733568134</pqid></control><display><type>article</type><title>Management of residual shunts after initial percutaneous patent foramen ovale closure: A single center experience with immediate and long-term follow-up</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Diaz, Tulio ; Cubeddu, Roberto J. ; Rengifo-Moreno, Pablo A. ; Cruz-Gonzalez, Ignacio ; Solis-Martin, Jorge ; Buonanno, Ferdinando S. ; Inglessis, Ignacio ; Palacios, Igor F.</creator><creatorcontrib>Diaz, Tulio ; Cubeddu, Roberto J. ; Rengifo-Moreno, Pablo A. ; Cruz-Gonzalez, Ignacio ; Solis-Martin, Jorge ; Buonanno, Ferdinando S. ; Inglessis, Ignacio ; Palacios, Igor F.</creatorcontrib><description>Background: Moderate‐to‐large residual shunts following percutaneous patent foramen ovale (PFO) closure are clinically important and associated with recurrent neuroembolic events. However, their management has not been clearly established in clinical practice. We report our experience in patients of these patients with a prior history of cryptogenic stroke and/or transient ischemic attack (TIA). Methods: All patients undergoing percutaneous PFO closure were routinely screened at six‐months for residual shunts using transthoracic 2D echocardiography with antecubital administration of agitated saline contrast and color flow Doppler. Patients with evidence of moderate‐to‐large residual shunts were selected to undergo reintervention with shunt closure. Postreintervention follow‐up was performed at 24‐hr, 30 days, and every six months thereafter. Clinical predictors of the moderate‐to‐large residual shunts, and the feasibility, safety and long‐term efficacy of percutaneous residual shunt closure using a second device implant were examined. Results: Between 1995 and 2007, a total of 424 patients underwent PFO closure. Of these, 5% (21/424) had moderate‐to‐large residual shunts. Baseline characteristics among patients with moderate‐to‐large residual shunts and those with only none or small defects (n = 403) were similar. Multivariate analysis identified the 24‐hr postprocedure shunt as the only independent predictor of residual shunting at six months. Of the 21 study patients with moderate‐to‐large residual shunt (mean age, 47 ± 14), one underwent successful elective surgical repair, while the remaining 20 underwent transcatheter closure using a second device. The technique was successful in 95% (19/20), and all but one patient had complete shunt closure at six months of their percutaneous reintervention. We report no deaths, recurrent strokes or TIAs during the long‐term mean follow‐up period of 2.9 years. Conclusions: Our study suggests that in patients with moderate‐to‐large residual PFO shunts, percutaneous reintervention using a second device implant is safe and effective. © 2010 Wiley‐Liss, Inc.</description><identifier>ISSN: 1522-1946</identifier><identifier>EISSN: 1522-726X</identifier><identifier>DOI: 10.1002/ccd.22475</identifier><identifier>PMID: 20578100</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Boston ; Cardiac Catheterization - adverse effects ; Cardiac Catheterization - instrumentation ; Catheterization ; CHDA ; CHDA, congenital heart disease in adults ; Chi-Square Distribution ; congenital heart disease in adults ; Echocardiography, Doppler, Color ; Female ; FIST ; FIST, fistula/shunts ; fistula/shunts ; Foramen Ovale, Patent - complications ; Foramen Ovale, Patent - diagnostic imaging ; Foramen Ovale, Patent - physiopathology ; Foramen Ovale, Patent - therapy ; Hemodynamics ; Humans ; Ischemic Attack, Transient - etiology ; Ischemic Attack, Transient - physiopathology ; Ischemic Attack, Transient - prevention & control ; Logistic Models ; Male ; Middle Aged ; ovale/atrial septal defect ; patent foramen ; PFO ; PFO, patent foramen ; Risk Assessment ; Risk Factors ; Septal Occluder Device ; Stroke - etiology ; Stroke - physiopathology ; Stroke - prevention & control ; Time Factors ; Treatment Outcome ; Young Adult</subject><ispartof>Catheterization and cardiovascular interventions, 2010-07, Vol.76 (1), p.145-150</ispartof><rights>Copyright © 2010 Wiley‐Liss, Inc.</rights><rights>(c) 2010 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3625-4a752a96d46a7b80f6a6de2be74abc91403fe6f6641759874047a34ac66eafb3</citedby><cites>FETCH-LOGICAL-c3625-4a752a96d46a7b80f6a6de2be74abc91403fe6f6641759874047a34ac66eafb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fccd.22475$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fccd.22475$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20578100$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Diaz, Tulio</creatorcontrib><creatorcontrib>Cubeddu, Roberto J.</creatorcontrib><creatorcontrib>Rengifo-Moreno, Pablo A.</creatorcontrib><creatorcontrib>Cruz-Gonzalez, Ignacio</creatorcontrib><creatorcontrib>Solis-Martin, Jorge</creatorcontrib><creatorcontrib>Buonanno, Ferdinando S.</creatorcontrib><creatorcontrib>Inglessis, Ignacio</creatorcontrib><creatorcontrib>Palacios, Igor F.</creatorcontrib><title>Management of residual shunts after initial percutaneous patent foramen ovale closure: A single center experience with immediate and long-term follow-up</title><title>Catheterization and cardiovascular interventions</title><addtitle>Cathet. Cardiovasc. Intervent</addtitle><description>Background: Moderate‐to‐large residual shunts following percutaneous patent foramen ovale (PFO) closure are clinically important and associated with recurrent neuroembolic events. However, their management has not been clearly established in clinical practice. We report our experience in patients of these patients with a prior history of cryptogenic stroke and/or transient ischemic attack (TIA). Methods: All patients undergoing percutaneous PFO closure were routinely screened at six‐months for residual shunts using transthoracic 2D echocardiography with antecubital administration of agitated saline contrast and color flow Doppler. Patients with evidence of moderate‐to‐large residual shunts were selected to undergo reintervention with shunt closure. Postreintervention follow‐up was performed at 24‐hr, 30 days, and every six months thereafter. Clinical predictors of the moderate‐to‐large residual shunts, and the feasibility, safety and long‐term efficacy of percutaneous residual shunt closure using a second device implant were examined. Results: Between 1995 and 2007, a total of 424 patients underwent PFO closure. Of these, 5% (21/424) had moderate‐to‐large residual shunts. Baseline characteristics among patients with moderate‐to‐large residual shunts and those with only none or small defects (n = 403) were similar. Multivariate analysis identified the 24‐hr postprocedure shunt as the only independent predictor of residual shunting at six months. Of the 21 study patients with moderate‐to‐large residual shunt (mean age, 47 ± 14), one underwent successful elective surgical repair, while the remaining 20 underwent transcatheter closure using a second device. The technique was successful in 95% (19/20), and all but one patient had complete shunt closure at six months of their percutaneous reintervention. We report no deaths, recurrent strokes or TIAs during the long‐term mean follow‐up period of 2.9 years. Conclusions: Our study suggests that in patients with moderate‐to‐large residual PFO shunts, percutaneous reintervention using a second device implant is safe and effective. © 2010 Wiley‐Liss, Inc.</description><subject>Adult</subject><subject>Aged</subject><subject>Boston</subject><subject>Cardiac Catheterization - adverse effects</subject><subject>Cardiac Catheterization - instrumentation</subject><subject>Catheterization</subject><subject>CHDA</subject><subject>CHDA, congenital heart disease in adults</subject><subject>Chi-Square Distribution</subject><subject>congenital heart disease in adults</subject><subject>Echocardiography, Doppler, Color</subject><subject>Female</subject><subject>FIST</subject><subject>FIST, fistula/shunts</subject><subject>fistula/shunts</subject><subject>Foramen Ovale, Patent - complications</subject><subject>Foramen Ovale, Patent - diagnostic imaging</subject><subject>Foramen Ovale, Patent - physiopathology</subject><subject>Foramen Ovale, Patent - therapy</subject><subject>Hemodynamics</subject><subject>Humans</subject><subject>Ischemic Attack, Transient - etiology</subject><subject>Ischemic Attack, Transient - physiopathology</subject><subject>Ischemic Attack, Transient - prevention & control</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>ovale/atrial septal defect</subject><subject>patent foramen</subject><subject>PFO</subject><subject>PFO, patent foramen</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Septal Occluder Device</subject><subject>Stroke - etiology</subject><subject>Stroke - physiopathology</subject><subject>Stroke - prevention & control</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1522-1946</issn><issn>1522-726X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctu1DAUhi0EohdY8ALIO8QireM49oRdFWhBGgoSlcrOOnGOpwbnUjth2jfp4-Ih0-5Y2Tr6_k865yfkTc5Ocsb4qTHtCedClc_IYV5ynikufz7f__NKyANyFOMvxlglefWSHHBWqlWKHpKHr9DDBjvsJzpYGjC6dgZP483cT5GCnTBQ17vJpeGIwcwT9DjMkY4w7UJ2CJDSdPgDHqnxQ5wDfqBnNLp-s5skKCnwLoUd9gbp1k031HUdti4pKPQt9UO_yRLWJZ33wzabx1fkhQUf8fX-PSZX55-u6s_Z-tvFl_psnZlC8jIToEoOlWyFBNWsmJUgW-QNKgGNqXLBCovSSilyVVYrJZhQUAgwUiLYpjgm7xbtGIbbGeOkOxcNer9sqVVRlHKVFyKR7xfShCHGgFaPwXUQ7nXO9K4GnWrQ_2pI7Nu9dW7Snk_k490TcLoAW-fx_v8mXdcfH5XZknBxwrunBITfWqoikdeXF_py_f1HzdW1Pi_-Am1wpAU</recordid><startdate>20100701</startdate><enddate>20100701</enddate><creator>Diaz, Tulio</creator><creator>Cubeddu, Roberto J.</creator><creator>Rengifo-Moreno, Pablo A.</creator><creator>Cruz-Gonzalez, Ignacio</creator><creator>Solis-Martin, Jorge</creator><creator>Buonanno, Ferdinando S.</creator><creator>Inglessis, Ignacio</creator><creator>Palacios, Igor F.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100701</creationdate><title>Management of residual shunts after initial percutaneous patent foramen ovale closure: A single center experience with immediate and long-term follow-up</title><author>Diaz, Tulio ; Cubeddu, Roberto J. ; Rengifo-Moreno, Pablo A. ; Cruz-Gonzalez, Ignacio ; Solis-Martin, Jorge ; Buonanno, Ferdinando S. ; Inglessis, Ignacio ; Palacios, Igor F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3625-4a752a96d46a7b80f6a6de2be74abc91403fe6f6641759874047a34ac66eafb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Boston</topic><topic>Cardiac Catheterization - adverse effects</topic><topic>Cardiac Catheterization - instrumentation</topic><topic>Catheterization</topic><topic>CHDA</topic><topic>CHDA, congenital heart disease in adults</topic><topic>Chi-Square Distribution</topic><topic>congenital heart disease in adults</topic><topic>Echocardiography, Doppler, Color</topic><topic>Female</topic><topic>FIST</topic><topic>FIST, fistula/shunts</topic><topic>fistula/shunts</topic><topic>Foramen Ovale, Patent - complications</topic><topic>Foramen Ovale, Patent - diagnostic imaging</topic><topic>Foramen Ovale, Patent - physiopathology</topic><topic>Foramen Ovale, Patent - therapy</topic><topic>Hemodynamics</topic><topic>Humans</topic><topic>Ischemic Attack, Transient - etiology</topic><topic>Ischemic Attack, Transient - physiopathology</topic><topic>Ischemic Attack, Transient - prevention & control</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>ovale/atrial septal defect</topic><topic>patent foramen</topic><topic>PFO</topic><topic>PFO, patent foramen</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Septal Occluder Device</topic><topic>Stroke - etiology</topic><topic>Stroke - physiopathology</topic><topic>Stroke - prevention & control</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Diaz, Tulio</creatorcontrib><creatorcontrib>Cubeddu, Roberto J.</creatorcontrib><creatorcontrib>Rengifo-Moreno, Pablo A.</creatorcontrib><creatorcontrib>Cruz-Gonzalez, Ignacio</creatorcontrib><creatorcontrib>Solis-Martin, Jorge</creatorcontrib><creatorcontrib>Buonanno, Ferdinando S.</creatorcontrib><creatorcontrib>Inglessis, Ignacio</creatorcontrib><creatorcontrib>Palacios, Igor F.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Catheterization and cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Diaz, Tulio</au><au>Cubeddu, Roberto J.</au><au>Rengifo-Moreno, Pablo A.</au><au>Cruz-Gonzalez, Ignacio</au><au>Solis-Martin, Jorge</au><au>Buonanno, Ferdinando S.</au><au>Inglessis, Ignacio</au><au>Palacios, Igor F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of residual shunts after initial percutaneous patent foramen ovale closure: A single center experience with immediate and long-term follow-up</atitle><jtitle>Catheterization and cardiovascular interventions</jtitle><addtitle>Cathet. Cardiovasc. Intervent</addtitle><date>2010-07-01</date><risdate>2010</risdate><volume>76</volume><issue>1</issue><spage>145</spage><epage>150</epage><pages>145-150</pages><issn>1522-1946</issn><eissn>1522-726X</eissn><abstract>Background: Moderate‐to‐large residual shunts following percutaneous patent foramen ovale (PFO) closure are clinically important and associated with recurrent neuroembolic events. However, their management has not been clearly established in clinical practice. We report our experience in patients of these patients with a prior history of cryptogenic stroke and/or transient ischemic attack (TIA). Methods: All patients undergoing percutaneous PFO closure were routinely screened at six‐months for residual shunts using transthoracic 2D echocardiography with antecubital administration of agitated saline contrast and color flow Doppler. Patients with evidence of moderate‐to‐large residual shunts were selected to undergo reintervention with shunt closure. Postreintervention follow‐up was performed at 24‐hr, 30 days, and every six months thereafter. Clinical predictors of the moderate‐to‐large residual shunts, and the feasibility, safety and long‐term efficacy of percutaneous residual shunt closure using a second device implant were examined. Results: Between 1995 and 2007, a total of 424 patients underwent PFO closure. Of these, 5% (21/424) had moderate‐to‐large residual shunts. Baseline characteristics among patients with moderate‐to‐large residual shunts and those with only none or small defects (n = 403) were similar. Multivariate analysis identified the 24‐hr postprocedure shunt as the only independent predictor of residual shunting at six months. Of the 21 study patients with moderate‐to‐large residual shunt (mean age, 47 ± 14), one underwent successful elective surgical repair, while the remaining 20 underwent transcatheter closure using a second device. The technique was successful in 95% (19/20), and all but one patient had complete shunt closure at six months of their percutaneous reintervention. We report no deaths, recurrent strokes or TIAs during the long‐term mean follow‐up period of 2.9 years. Conclusions: Our study suggests that in patients with moderate‐to‐large residual PFO shunts, percutaneous reintervention using a second device implant is safe and effective. © 2010 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>20578100</pmid><doi>10.1002/ccd.22475</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1522-1946 |
ispartof | Catheterization and cardiovascular interventions, 2010-07, Vol.76 (1), p.145-150 |
issn | 1522-1946 1522-726X |
language | eng |
recordid | cdi_proquest_miscellaneous_733568134 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Adult Aged Boston Cardiac Catheterization - adverse effects Cardiac Catheterization - instrumentation Catheterization CHDA CHDA, congenital heart disease in adults Chi-Square Distribution congenital heart disease in adults Echocardiography, Doppler, Color Female FIST FIST, fistula/shunts fistula/shunts Foramen Ovale, Patent - complications Foramen Ovale, Patent - diagnostic imaging Foramen Ovale, Patent - physiopathology Foramen Ovale, Patent - therapy Hemodynamics Humans Ischemic Attack, Transient - etiology Ischemic Attack, Transient - physiopathology Ischemic Attack, Transient - prevention & control Logistic Models Male Middle Aged ovale/atrial septal defect patent foramen PFO PFO, patent foramen Risk Assessment Risk Factors Septal Occluder Device Stroke - etiology Stroke - physiopathology Stroke - prevention & control Time Factors Treatment Outcome Young Adult |
title | Management of residual shunts after initial percutaneous patent foramen ovale closure: A single center experience with immediate and long-term follow-up |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T01%3A36%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20residual%20shunts%20after%20initial%20percutaneous%20patent%20foramen%20ovale%20closure:%20A%20single%20center%20experience%20with%20immediate%20and%20long-term%20follow-up&rft.jtitle=Catheterization%20and%20cardiovascular%20interventions&rft.au=Diaz,%20Tulio&rft.date=2010-07-01&rft.volume=76&rft.issue=1&rft.spage=145&rft.epage=150&rft.pages=145-150&rft.issn=1522-1946&rft.eissn=1522-726X&rft_id=info:doi/10.1002/ccd.22475&rft_dat=%3Cproquest_cross%3E733568134%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733568134&rft_id=info:pmid/20578100&rfr_iscdi=true |